Transcriptional Repressors of Fetal Globin Genes as Novel Therapeutic Targets in Beta-Thalassemia

During development the human β-globin gene cluster undergoes two switching processes at the embryo-fetal and fetal-adult stages, respectively, involving changes in chromatin remodeling and in transcriptional regulatory networks. In particular, during the perinatal period, the switch from fetal-to-ad...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Martino, Marianna De, Sessa, Raffaele, Storino, Maria Rosaria, Giuliano, Mariarosaria, Trombetti, Silvia, Catapano, Rosa, Bianco, Alessandra Lo, Izzo, Paola, Grosso, Michela
Formato: Capítulo de libro
Lenguaje:inglés
Publicado: IntechOpen 2020
Materias:
Acceso en línea:https://www.intechopen.com/chapters/70744
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:During development the human β-globin gene cluster undergoes two switching processes at the embryo-fetal and fetal-adult stages, respectively, involving changes in chromatin remodeling and in transcriptional regulatory networks. In particular, during the perinatal period, the switch from fetal-to-adult globin gene expression leads to fetal globin genes silencing and progressive decline of fetal hemoglobin (HbF). Impaired hemoglobin switching is associated with hereditary persistence of HbF (HPFH), a condition in which the fetal globin genes fail to be completely silenced in adult red blood cells. This condition, when co-inherited with hemoglobinopathies, has great therapeutic potential because elevated HbF levels can ameliorate β-thalassemia and sickle cell anemia. Therefore, there is a growing interest about the complex network of factors that regulate fetal globin genes expression. Here we discuss the activity of transcriptional repressors of fetal globin genes and their potential role as novel therapeutic targets in β-thalassemia.
ISBN:978-1-83880-586-9
DOI:10.5772/intechopen.90762